Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer - Authors' response.
Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA; Abramson Cancer Center, Department of Medicine, Haematology/Oncology, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA. Electronic address: brosem@mail.med.upenn.edu.
Marcia S
MS
Brose
Abramson Cancer Center, Department of Medicine, Haematology/Oncology, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA.
Nathan
N
Singh
D006801:Humans; D007211:Indoles; D048493:Proto-Oncogene Proteins B-raf; D013449:Sulfonamides; D013964:Thyroid Neoplasms; D000077484:Vemurafenib
D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf